1. Current Management and Future Directions for Pulmonary Arterial Hypertension Associated with Congenital Heart Disease.
- Author
-
Mahmoud, Ahmed K., Abbas, Mohammed Tiseer, Kamel, Moaz A., Farina, Juan M., Pereyra, Milagros, Scalia, Isabel G., Barry, Timothy, Chao, Chieh-Ju, Marcotte, Francois, Ayoub, Chadi, Scott, Robert L., Majdalany, David S., and Arsanjani, Reza
- Subjects
PULMONARY arterial hypertension ,CONGENITAL heart disease ,MEDICAL personnel ,CARDIAC patients ,PULMONARY hypertension ,DISEASE management - Abstract
Current management of patients with congenital heart disease has increased their survival into adulthood. This is accompanied by potential cardiac complications, including pulmonary hypertension associated with congenital heart disease (PAH-CHD). PAH-CHD constitutes a challenging subgroup of pulmonary hypertension and requires expert management to improve quality of life and prognosis. Novel agents have shown a significant improvement in morbidity and mortality in patients with pulmonary arterial hypertension. However, the long-term effects of these medications on PAH-CHD patients remain somewhat uncertain, necessitating treatment plans largely founded on the clinical experience of the healthcare providers. The aim of this review is to summarize the current evidence and future perspectives regarding treatment strategies for PAH-CHD to help better guide management of this complex disease. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF